C2N Diagnostics Receives SBIR Award to Study Novel Tau Biomarkers in Alzheimer's Disease

August 7, 2012 ST. LOUIS, MO – C2N Diagnostics today announced that it has received a Small Business Innovation Research (SBIR) Award from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). The award will fund the development of assays for investigating Tau biology. Tau is a protein strongly implicated in the progression of Alzheimer's disease. Dr. Tim West, C2N's VP of Research and Development, will serve as the study's principal investigator.

Stated Dr. West, "We are excited that the NIA has decided to continue to support our research and development of novel mass spectrometer based analyses of proteins involved in Alzheimer's disease. We are currently completing another NIA sponsored project investigating the biology of amyloid-beta (Aβ) isoforms in individuals with and without Alzheimer's pathology. This new grant will expand the reach of our proprietary technology platform into new areas of protein biology in Alzheimer's disease. We look forward to offering the developed technology to our industry collaborators, working on novel candidate therapies to address the global health concern of Alzheimer's disease and other forms of neurodegeneration."

About C2N Diagnostics

C2N Diagnostics, LLC formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, the Washington University Office of Technology Management, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). C2N is developing a suite of novel biomarker assays and tools to assist in pre-clinical drug discovery, clinical drug development, and the early detection and assessment of progression of debilitating neurodegenerative disorders. The company's products include the SILK-Ab® and SISAQ-Ab™ Assays, which rely upon stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. Beyond Alzheimer's disease, products are in development to target Parkinson's disease, Huntington’s disease, brain injury, schizophrenia, and amyotrophic lateral sclerosis (ALS), among others. For additional information, see www.C2Ndiagnostics.com or call 1-877-C2N-DIAG (1-877-226-3424).

Acknowledgement and Disclaimer

The project described above is being supported by Award Number R43 AG043206-01 from the National Institute on Aging. The content is solely the responsibility of C2N Diagnostics and its authors, and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health.

About C2N Diagnostics

C2N Diagnostics, LLC (www.C2Ndiagnostics.com) formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, the Washington University Office of Technology Management, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). C2N is developing a suite of novel biomarker assays and tools to assist in pre-clinical drug discovery, clinical drug development, and the early detection and assessment of progression of debilitating neurodegenerative disorders. The company’s products include the SILK-Aβ®, SISAQ-Aβ™, and SISAQ-Tau™ Assays, which rely upon stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. Beyond AD, products are in development to target Parkinson’s disease, Huntington’s disease, brain injury, schizophrenia, and amyotrophic lateral sclerosis (ALS), among others. For additional information, please contact info@C2Ndiagnostics.com or call 1-877-C2N-DIAG (1-877-226-3424).